← Back to Search

Vitamin Supplement

4000 IU Vitamin D for Osler-Weber-Rendu Syndrome

Phase 2
Waitlist Available
Research Sponsored by St. Paul's Hospital, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 months, and 6 months
Awards & highlights

Study Summary

The study aims to assess whether supplementing vitamin D in patients diagnosed with Hereditary Haemorrhagic Telangiectasia (HHT) will decrease the frequency and severity of nosebleeds these patients experience. It is hypothesized that the larger the dose of daily vitamin D given to the patients, the less frequent and less severe the nosebleeds will be.

Eligible Conditions
  • Osler-Weber-Rendu Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 months, and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 months, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Epistaxis Severity Score
Secondary outcome measures
Change in Modified Lund-Kennedy Score

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 4000 IU Vitamin DExperimental Treatment1 Intervention
Group II: 1000 IU Vitamin DExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vit D
2016
Completed Phase 4
~1210

Find a Location

Who is running the clinical trial?

St. Paul's Hospital, CanadaLead Sponsor
44 Previous Clinical Trials
12,660 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
formation/NLM/NIH, NCBI. “Gprobe”. 2017. Web. <https://github.com/ncbi/gprobe>..Journal
Gprobe
Information/NLM/NIH, NCBI. 2017. “Gprobe”. GitHub repository. https://github.com/ncbi/gprobe.
The LaryngoscopeJournal
An Epistaxis Severity Score for Hereditary Hemorrhagic Telangiectasia
Hoag, Jeffrey B., Peter Terry, Sally Mitchell, Douglas Reh, and Christian A. Merlo. 2010. “An Epistaxis Severity Score for Hereditary Hemorrhagic Telangiectasia”. The Laryngoscope. Wiley. doi:10.1002/lary.20818.
The LaryngoscopeJournal
An Epistaxis Severity Score for Hereditary Hemorrhagic Telangiectasia
Hoag, Jeffrey B., Peter Terry, Sally Mitchell, Douglas Reh, and Christian A. Merlo. 2010. “An Epistaxis Severity Score for Hereditary Hemorrhagic Telangiectasia”. The Laryngoscope. Wiley. doi:10.1002/lary.20818.
The LaryngoscopeJournal
An Epistaxis Severity Score for Hereditary Hemorrhagic Telangiectasia
Hoag, Jeffrey B., Peter Terry, Sally Mitchell, Douglas Reh, and Christian A. Merlo. 2010. “An Epistaxis Severity Score for Hereditary Hemorrhagic Telangiectasia”. The Laryngoscope. Wiley. doi:10.1002/lary.20818.
All > Hereditary Angioedema
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top